Chemocentryx Stock Story


USD 50.87  0.08  0.16%   

The stock goes through a very aggressive trading activities. Because some millenniums are getting more into healthcare space, we are going to concentrate on the feasibility of inclusion Chemocentryx into your portfolio. What exactly are Chemocentryx shareholders getting in June?
Published over two months ago
View all stories for Chemocentryx | View All Stories

What are the current analyst consensus on Chemocentryx (NASDAQ:CCXI)?

Chemocentryx's average rating is Buy from 6 analysts.
Our investment recommendation module complements current analysts and expert consensus on Chemocentryx. It analyzes the firm potential to grow using all fundamental, technical, and market related data available at the time.
What is the right price you would pay to acquire a share of Chemocentryx? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Chemocentryx this year

Annual and quarterly reports issued by Chemocentryx are formal financial statements that are published yearly and quarterly and sent to Chemocentryx stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Chemocentryx often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How does Chemocentryx utilize its cash?

To perform a cash flow analysis of Chemocentryx, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Chemocentryx is receiving and how much cash it distributes out in a given period. The Chemocentryx cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Chemocentryx Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (75.62 Million)

Acquisition by Herron Jennifer Lyn of 17237 shares of Chemocentryx subject to Rule 16b-3

Legal trades by Chemocentryx insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Chemocentryx insider trading alert for grant of common stock by Herron Jennifer Lyn, the corporate stakeholder, on 30th of June 2022. This event was filed by Chemocentryx Inc with SEC on 2022-06-30. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.


Earning per share calculations of Chemocentryx is based on official Zacks consensus of 4 analysts regarding Chemocentryx's future annual earnings. Given the historical accuracy of 76.36%, the future earnings per share of the company is estimated to be -1.66 with the lowest and highest values of -1.91 and -1.25, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.

Is Chemocentryx a risky opportunity?

Let's check the volatility. Chemocentryx is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Chemocentryx (NASDAQ:CCXI) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a Chemocentryx stock makes you a part-owner of that company.

Chemocentryx Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Chemocentryx. The Chemocentryx consensus assessment is calculated by taking the average estimates from all of the analysts covering Chemocentryx

Strong Buy
Strong Buy583.33
Strong Sell00.0

Our perspective of the current Chemocentryx rise

Current skewness is at 0.17. Chemocentryx exhibits very low volatility with skewness of 0.17 and kurtosis of 1.71. However, we advise investors to further study Chemocentryx technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Chemocentryx's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Chemocentryx's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Chemocentryx Implied Volatility

Chemocentryx's implied volatility exposes the market's sentiment of Chemocentryx stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Chemocentryx's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Chemocentryx stock will not fluctuate a lot when Chemocentryx's options are near their expiration.

Our Final Take On Chemocentryx

While some other entities in the biotechnology industry are either recovering or due for a correction, Chemocentryx may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor quit any shares of Chemocentryx at this time. The Chemocentryx risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Chemocentryx.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Chemocentryx. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to